Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Curr Hepatol Rep. 2018 Sep 20;17(4):377–384. doi: 10.1007/s11901-018-0424-8

Table 1.

Summary of the main findings of recent studies examining de novo or recurrent HCC risk following DAA therapy

Outcome Study designs Representative
studies
Main Findings
De novo HCC
DAA with SVR vs.
Treatment failure
(8, 9, 11) Lower risk of HCC in patients with SVR after
DAAs compared to patients without SVR
DAA vs.
No treatment
(10, 12) Lower risk of HCC in patients receiving DAAs
compared to patients remaining untreated

DAA vs.
IFN
(7, 9, 12)
No difference in risk of HCC with DAA
treatment compared to IFN treatment
Recurrent HCC
DAA treated
patients only
(13, 15) Higher than expected proportion of patients
with recurrent HCC after starting DAA therapy
DAA treated vs.
control
(3841) No difference in risk of recurrent HCC with DAA
treatment compared to no treatment or IFN-
treated patients